Daiichi Sankyo (DSNKY) Stock Price, News & Analysis

Company Overview

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

Key Stats

• Today's Range: $25.31 to $26.53
• 50-Day Range: $25.97 to $32.92
• 52-Week Range: $25.11 to $42.48
• Volume: 232,377 shs
• Average Volume: 183,097 shs
• Market Capitalization: $50.13 billion
• P/E Ratio: 0.23
• Dividend Yield: 84.98%
• Price Target: N/A
• Consensus Rating: N/A

Daiichi Sankyo Stock Analysis - MarketRank™

Daiichi Sankyo scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Daiichi Sankyo.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Daiichi Sankyo is 0.23, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 110.95.

Price to Earnings Ratio vs. Sector

The P/E ratio of Daiichi Sankyo is 0.23, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.15.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the outstanding shares of Daiichi Sankyo have been sold short.

Short Interest Ratio / Days to Cover

Daiichi Sankyo has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Daiichi Sankyo has recently increased by 896.36%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Daiichi Sankyo pays a meaningful dividend of 3.12%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Daiichi Sankyo does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Daiichi Sankyo is 19.59%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the outstanding shares of Daiichi Sankyo have been sold short.

Short Interest Ratio / Days to Cover

Daiichi Sankyo has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Daiichi Sankyo has recently increased by 896.36%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.34

News Sentiment

Daiichi Sankyo has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Daiichi Sankyo this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Daiichi Sankyo insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 0.05% of the stock of Daiichi Sankyo is held by institutions.

DSNKY Stock Analysis - Frequently Asked Questions

How have DSNKY shares performed this year?

Daiichi Sankyo's stock was trading at $27.29 at the beginning of 2025. Since then, DSNKY shares have decreased by 3.1% and is now trading at $26.44.
View the best growth stocks for 2025 here.

How do I buy shares of Daiichi Sankyo?

Shares of DSNKY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - General
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:DSNKY
• Previous Symbol: OTCMKTS:DSNKY
• CUSIP: N/A
• CIK: N/A
• Web: www.daiichisankyo.com
• Phone: (136) 225-1111
• Fax: N/A
• Employees: 17,435
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 0.23
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,896,105,000
• Free Float: N/A
• Market Cap: $50.13 billion
• Optionable: Not Optionable
• Beta: N/A